| Clinical data | |
|---|---|
| Trade names | Pulmozyme |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694002 |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | |
| Chemical and physical data | |
| Formula | C1321H1999N339O396S9 |
| Molar mass | 29253.9 g·mol−1 |
| (what is this?)(verify) |
Dornase alfa (proprietary name Pulmozyme from Genentech) is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus of cystic fibrosis patients and reduces viscosity in the lungs, promoting improved clearance of secretions. This protein therapeutic agent is produced in Chinese hamster ovary cells. Cached.
Cystic fibrosis[edit]
- Kay Clow is on Facebook. Join Facebook to connect with Kay Clow and others you may know. Facebook gives people the power to share and makes the world.
- Willkommen bei Alfamed Willkommen bei Alfamed Willkommen bei Alfamed. Laser- und Kosmetikzentrum. Willkommen bei Alfamed.
Dornase alfa is the most recent therapeutic agent developed with this basic mechanism of action. Prior to the cloning of the human enzyme, bovine DNase I was on the market for many years, though its utility was limited by the inherent antigenic response to a cow protein in the lungs of patients. Other DNases, such as DNase II, have therapeutic potential as well, but no further DNases have been brought to market yet for cystic fibrosis.
The Venza has a bunch of driver-assistance features standard, like automated emergency braking, land-departure warning, and adaptable cruise control on every model. Per Toyota's hybrid powertrain. The driver's insurance may cover some personal injury or medical expenses. It may also supplement your insurance coverage, if the cost of damages caused by your vehicle is higher than the amount your policy can pay. AlfaMed boasts an experience of over twenty-five years in this business. It began as an authorized dealer in some regions of Central Italy and since 2007 it has become an importer and distributor for the Italian market of certain products for Pain Therapy and Spine Surgery, positioning itself in the market with high-technology, innovative.
Dornase alfa is an orphan drug.[1]
Contraindications[edit]
- Hypersensitivity to dornase alfa
- Hypersensitivity to Chinese hamster ovary cell products
Economy[edit]
Dornase alpha 1000 units (1 mg/ml)2.5ml (2500units) = £18.52 (GBP) Drivers steinberg media usb devices.
Off label use[edit]
Dornase alfa has recently been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis where other therapies have failed.[2][3]
Drivers Alfa Media
In studies conducted, Dornase alfa has been thought to help resolve mucus secretion in CoViD-19 patients as well as in the treatment of cystic fibrosis, but since it is taken with nebulizer in general use and there is a possibility of aerosolization of the virus, it is not preferred in most medical centers to avoid secondary infections.[4]
Drivers Alfa Medical Card
References[edit]
Drivers Alfa Medical
- ^Collier, Joe (1 September 1995). 'Dornase-alfa and orphan drugs'. The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID7651014. S2CID5456247.
- ^Erdeve O, Uras N, Atasay B, Arsan S (2007). 'Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series'. Croat Med J. 48 (2): 234–9. PMC2080511. PMID17436388.
- ^Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). 'DNase and atelectasis in non-cystic fibrosis pediatric patients'. Crit Care. 9 (4): R351-6. doi:10.1186/cc3544. PMC1269442. PMID16137347.
- ^Barnes, Betsy J.; Adrover, Jose M.; Baxter-Stoltzfus, Amelia; Borczuk, Alain; Cools-Lartigue, Jonathan; Crawford, James M.; Daßler-Plenker, Juliane; Guerci, Philippe; Huynh, Caroline; Knight, Jason S.; Loda, Massimo (2020-06-01). 'Targeting potential drivers of COVID-19: Neutrophil extracellular traps'. Journal of Experimental Medicine. 217 (6). doi:10.1084/jem.20200652. ISSN0022-1007. PMC7161085. PMID32302401.
| Clinical data | |
|---|---|
| Trade names | Pulmozyme |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694002 |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | |
| Chemical and physical data | |
| Formula | C1321H1999N339O396S9 |
| Molar mass | 29253.9 g·mol−1 |
| (what is this?)(verify) |
Dornase alfa (proprietary name Pulmozyme from Genentech) is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus of cystic fibrosis patients and reduces viscosity in the lungs, promoting improved clearance of secretions. This protein therapeutic agent is produced in Chinese hamster ovary cells. Cached.
Cystic fibrosis[edit]
- Kay Clow is on Facebook. Join Facebook to connect with Kay Clow and others you may know. Facebook gives people the power to share and makes the world.
- Willkommen bei Alfamed Willkommen bei Alfamed Willkommen bei Alfamed. Laser- und Kosmetikzentrum. Willkommen bei Alfamed.
Dornase alfa is the most recent therapeutic agent developed with this basic mechanism of action. Prior to the cloning of the human enzyme, bovine DNase I was on the market for many years, though its utility was limited by the inherent antigenic response to a cow protein in the lungs of patients. Other DNases, such as DNase II, have therapeutic potential as well, but no further DNases have been brought to market yet for cystic fibrosis.
The Venza has a bunch of driver-assistance features standard, like automated emergency braking, land-departure warning, and adaptable cruise control on every model. Per Toyota's hybrid powertrain. The driver's insurance may cover some personal injury or medical expenses. It may also supplement your insurance coverage, if the cost of damages caused by your vehicle is higher than the amount your policy can pay. AlfaMed boasts an experience of over twenty-five years in this business. It began as an authorized dealer in some regions of Central Italy and since 2007 it has become an importer and distributor for the Italian market of certain products for Pain Therapy and Spine Surgery, positioning itself in the market with high-technology, innovative.
Dornase alfa is an orphan drug.[1]
Contraindications[edit]
- Hypersensitivity to dornase alfa
- Hypersensitivity to Chinese hamster ovary cell products
Economy[edit]
Dornase alpha 1000 units (1 mg/ml)2.5ml (2500units) = £18.52 (GBP) Drivers steinberg media usb devices.
Off label use[edit]
Dornase alfa has recently been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis where other therapies have failed.[2][3]
Drivers Alfa Media
In studies conducted, Dornase alfa has been thought to help resolve mucus secretion in CoViD-19 patients as well as in the treatment of cystic fibrosis, but since it is taken with nebulizer in general use and there is a possibility of aerosolization of the virus, it is not preferred in most medical centers to avoid secondary infections.[4]
Drivers Alfa Medical Card
References[edit]
Drivers Alfa Medical
- ^Collier, Joe (1 September 1995). 'Dornase-alfa and orphan drugs'. The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID7651014. S2CID5456247.
- ^Erdeve O, Uras N, Atasay B, Arsan S (2007). 'Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series'. Croat Med J. 48 (2): 234–9. PMC2080511. PMID17436388.
- ^Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). 'DNase and atelectasis in non-cystic fibrosis pediatric patients'. Crit Care. 9 (4): R351-6. doi:10.1186/cc3544. PMC1269442. PMID16137347.
- ^Barnes, Betsy J.; Adrover, Jose M.; Baxter-Stoltzfus, Amelia; Borczuk, Alain; Cools-Lartigue, Jonathan; Crawford, James M.; Daßler-Plenker, Juliane; Guerci, Philippe; Huynh, Caroline; Knight, Jason S.; Loda, Massimo (2020-06-01). 'Targeting potential drivers of COVID-19: Neutrophil extracellular traps'. Journal of Experimental Medicine. 217 (6). doi:10.1084/jem.20200652. ISSN0022-1007. PMC7161085. PMID32302401.
